$210 Million is the total value of Tamarack Advisers, LP's 28 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVCR | New | NOVOCURE LTDequity | $24,307,000 | – | 1,115,000 | +100.0% | 11.56% | – |
| NUVA | Buy | NUVASIVE INCequity | $18,796,000 | +52.8% | 360,000 | +71.2% | 8.94% | +33.1% |
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $18,216,000 | -8.9% | 1,475,000 | +7.3% | 8.66% | -20.7% |
| MDT | New | MEDTRONIC PLCequity | $15,242,000 | – | 190,000 | +100.0% | 7.25% | – |
| CORI | Buy | CORIUM INTERNATIONAL INCequity | $12,674,000 | +30.6% | 1,105,000 | +9.4% | 6.03% | +13.8% |
| GILD | Buy | GILEAD SCIENCES INCequity | $12,439,000 | +33.6% | 165,000 | +26.9% | 5.92% | +16.4% |
| XRAY | New | DENTSPLY SIRONA INCequity | $11,823,000 | – | 235,000 | +100.0% | 5.62% | – |
| SRCL | Buy | STERICYCLE INCequity | $11,706,000 | +179.3% | 200,000 | +224.5% | 5.57% | +143.4% |
| BIO | New | BIO-RAD LABORATORIES-Aequity | $9,478,000 | – | 37,900 | +100.0% | 4.51% | – |
| NXTM | Buy | NXSTAGE MEDICAL INCequity | $9,155,000 | +37.4% | 368,260 | +33.9% | 4.36% | +19.7% |
| QDEL | Sell | QUIDEL CORPequity | $8,549,000 | -27.0% | 165,000 | -38.9% | 4.07% | -36.4% |
| LH | Sell | LABORATORY CRP OF AMER HLDGSequity | $7,602,000 | -40.4% | 47,000 | -41.2% | 3.62% | -48.1% |
| ALKS | Buy | ALKERMES PLCequity | $6,376,000 | +66.4% | 110,000 | +57.1% | 3.03% | +45.1% |
| VSI | New | VITAMIN SHOPPE INCequity | $4,870,000 | – | 1,119,559 | +100.0% | 2.32% | – |
| CRME | CARDIOME PHARMA CORPequity | $4,350,000 | +49.7% | 1,875,000 | 0.0% | 2.07% | +30.5% | |
| SCI | Buy | SERVICE CORP INTERNATIONALequity | $4,340,000 | +16.3% | 115,000 | +15.0% | 2.06% | +1.3% |
| STE | Buy | STERIS PLCequity | $4,201,000 | +92.1% | 45,000 | +80.0% | 2.00% | +67.3% |
| ATRC | Buy | ATRICURE INCequity | $4,125,000 | +29.2% | 201,000 | +14.9% | 1.96% | +12.6% |
| PCRX | Sell | PACIRA PHARMACEUTICALS INCequity | $3,698,000 | -74.3% | 118,702 | -62.3% | 1.76% | -77.6% |
| LNTH | Buy | LANTHEUS HOLDINGS INCequity | $3,427,000 | +11.4% | 215,558 | +43.3% | 1.63% | -2.9% |
| HOLX | New | HOLOGIC INCequity | $2,802,000 | – | 75,000 | +100.0% | 1.33% | – |
| CERN | New | CERNER CORPequity | $2,610,000 | – | 45,000 | +100.0% | 1.24% | – |
| OPHT | Buy | OPHTHOTECH CORPequity | $2,326,000 | -0.6% | 848,840 | +13.2% | 1.11% | -13.4% |
| STRM | Buy | STREAMLINE HEALTH SOLUTIONSequity | $2,018,000 | +13.7% | 1,096,703 | +4.4% | 0.96% | -0.9% |
| LMNX | New | LUMINEX CORPequity | $1,997,000 | – | 94,757 | +100.0% | 0.95% | – |
| OPTN | New | OPTINOSE INCequity | $1,648,000 | – | 82,315 | +100.0% | 0.78% | – |
| OBLN | Sell | OBALON THERAPEUTICS INCequity | $1,458,000 | -63.5% | 425,000 | -29.6% | 0.69% | -68.2% |
| New | CVS US 04/20/18 C60call | $0 | – | 750 | +100.0% | 0.00% | – | |
| SHPG | Exit | SHPG US 01/19/18 C185call | $0 | – | -394 | -100.0% | -0.00% | – |
| TMO | Exit | TMO US 01/19/18 P195put | $0 | – | -100 | -100.0% | -0.03% | – |
| IWM | Exit | IWM US 01/19/18 P146put | $0 | – | -2,000 | -100.0% | -0.05% | – |
| SPY | Exit | SPY US 01/19/18 P255put | $0 | – | -4,000 | -100.0% | -0.09% | – |
| XLV | Exit | XLV US 01/19/18 P84put | $0 | – | -2,000 | -100.0% | -0.13% | – |
| BSX | Exit | BSX US 01/19/18 P27put | $0 | – | -1,500 | -100.0% | -0.18% | – |
| HCA | Exit | HCA US 01/19/18 C80call | $0 | – | -1,000 | -100.0% | -0.46% | – |
| RCM | Exit | R1 RCM INC | $0 | – | -400,000 | -100.0% | -0.96% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -92,600 | -100.0% | -1.71% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -25,000 | -100.0% | -2.13% | – |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -50,000 | -100.0% | -2.69% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -105,000 | -100.0% | -3.42% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -150,000 | -100.0% | -6.61% | – |
| Exit | NOVOCURE LTD | $0 | – | -1,055,000 | -100.0% | -11.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.